A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2026 - P3 | N=473 | Active, not recruiting | Sponsor: Celltrion | Trial primary completion date: Nov 2027 ➔ Mar 2027 | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2029 ➔ Sep 2028
Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
|